Introduction: Individuals suffering from psychiatric disorders experience high levels of illness burden and a significantly reduced quality of life. Despite targeted psychopharmacological strategies and complementary psychotherapeutic procedures only moderate effects are obtained, and the risk of relapse is high in many patients. Worldwide, psychiatric diseases such as depression are continuously increasing, challenging the personal life of the affected as well as their families, but also whole societies by increasing disability, early retirement and hospitalization. According to current scientific knowledge psychiatric disorders are caused by a multifactorial pathogenesis, including genetics, inflammation and neurotransmitter imbalance; furthermore, also lifestyle-associated factors gain rising importance. In line with this, there is growing evidence that the gut microbiota and nutrition have an impact on the onset and course of psychiatric disorders. Aim: This narrative review highlights the important role of nutrition in psychiatric care and underlines the significance of nutritional advice in the multifactorial, biopsychosocial treatment of patients. It focuses on current dietary interventions such as the Mediterranean diet, dietary supplements and modifications of the gut microbiota with pre-, pro- and postbiotics. Results: Recent studies support the connection between the quality of diet, gut microbiota and mental health through regulation of metabolic functions, anti-inflammatory and antiapoptotic properties and the support of neurogenesis. Dietary coaching to improve mental health seems to be an additional, cost-effective, practical, nonpharmacological intervention for individuals with psychiatric disorders. Conclusion: The use of nutritional interventions in psychiatry equips therapists with a promising tool for both the prevention and treatment of psychiatric disorders. Besides pharmacological therapy, psychotherapy and physical activity, nutritional interventions are an important pillar in the multifactorial, biopsychosocial treatment of psychiatric disease and could be used as a potential therapeutic target.

Keywords:
Nutrition, Psychiatry, Depression, Diet, Nutrients, Gut microbiome, Gut-brain axis, Mediterranean diet
1.
Baxter AJ, Patton G, Scott KM, Degenhardt L, Whiteford HA: Global epidemiology of mental disorders: what are we missing? PLoS One 2013; 8:e65514.
2.
Whiteford HA, Degenhardt L, Rehm J, Baxter AJ, Ferrari AJ, Erskine HE, Charlson FJ, Norman RE, Flaxman AD, Johns N: Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010. Lancet 2013; 382: 1575–1586.
3.
Klesse C, Berger M, Bermejo I, Bschor T, Gensichen J, Harfst T, Hautzinger M, Kolada C, Kühner C, Matzat J: Evidenzbasierte Psychotherapie der Depression. Psychotherapeut 2010; 55: 247–263.
4.
Sansone RA, Sansone LA: Antidepressant adherence: are patients taking their medications? Innov Clin Neurosci 2012; 9: 41.
5.
Logan AC, Jacka FN: Nutritional psychiatry research: an emerging discipline and its intersection with global urbanization, environmental challenges and the evolutionary mismatch. J Physiol Anthropol 2014; 33: 22.
6.
Jacka FN, Sacks G, Berk M, Allender S: Food policies for physical and mental health. BMC Psychiatry 2014; 14: 132.
7.
Rust P, Hasenegger V, König J: Österreichischer Ernährungsbericht 2017. Wien, Universität Wien und Bundesministerium für Gesundheit und Frauen, 2017.
8.
Parker E, Goldman J, Moshfegh A: America’s nutrition report card: comparing WWEIA, NHANES 2007–2010 usual nutrient intakes to dietary reference intakes (384.2). FASEB J 2014; 28: 384.382.
9.
Slavin J: Why whole grains are protective: biological mechanisms. Proc Nutr Soc 2003; 62: 129–134.
10.
Berk M, Williams LJ, Jacka FN, O’Neil A, Pasco JA, Moylan S, Allen NB, Stuart AL, Hayley AC, Byrne ML: So depression is an inflammatory disease, but where does the inflammation come from? BMC Med 2013; 11: 200.
11.
Guasch-Ferré M, Salas-Salvadó J, Ros E, Estruch R, Corella D, Fitó M, Martinez-Gonzalez M, Arós F, Gómez-Gracia E, Fiol M: The PREDIMED trial, Mediterranean diet and health outcomes: how strong is the evidence? Nutr Metab Cardiovasc Dis 2017; 27: 624–632.
12.
Molendijk M, Molero P, Sánchez-Pedreño FO, Van der Does W, Martínez-González MA: Diet quality and depression risk: a systematic review and dose-response meta-analysis of prospective studies. J Affect Disord 2018; 226: 346–354.
13.
Molendijk ML, Bus BA, Spinhoven P, Penninx BW, Kenis G, Prickaerts J, Voshaar RO, Elzinga BM: Serum levels of brain-derived neurotrophic factor in major depressive disorder: state-trait issues, clinical features and pharmacological treatment. Mol Psychiatry 2011; 16: 1088.
14.
Hansen SN, Ipsen DH, Schou-Pedersen AM, Lykkesfeldt J, Tveden-Nyborg P: Long term westernized diet leads to region-specific changes in brain signaling mechanisms. Neurosci Lett 2018; 676: 85–91.
15.
Sarris J, Logan AC, Akbaraly TN, Amminger GP, Balanzá-Martínez V, Freeman MP, Hibbeln J, Matsuoka Y, Mischoulon D, Mizoue T: Nutritional medicine as mainstream in psychiatry. Lancet Psychiatry 2015; 2: 271–274.
16.
Lai JS, Hiles S, Bisquera A, Hure AJ, McEvoy M, Attia J: A systematic review and meta-analysis of dietary patterns and depression in community-dwelling adults. Am J Clin Nutr 2013; 99: 181–197.
17.
Nanri A, Mizoue T, Poudel-Tandukar K, Noda M, Kato M, Kurotani K, Goto A, Oba S, Inoue M, Tsugane S: Dietary patterns and suicide in Japanese adults: the Japan Public Health Centre-based Prospective Study. Br J Psychiatry 2013; 203: 422–407.
18.
Susser ES, Lin SP: Schizophrenia after prenatal exposure to the Dutch Hunger Winter of 1944–1945. Arch Gen Psychiatry 1992; 49: 983–988.
19.
Brown AS, Susser ES, Lin SP, Neugebauer R, Gorman JM: Increased risk of affective disorders in males after second trimester prenatal exposure to the Dutch hunger winter of 1944–45. Br J Psychiatry 1995; 166: 601–606.
20.
O’Neil A, Quirk SE, Housden S, Brennan SL, Williams LJ, Pasco JA, Berk M, Jacka FN: Relationship between diet and mental health in children and adolescents: a systematic review. Am J Publ Health 2014; 104:e31–e42.
21.
Dipasquale S, Pariante CM, Dazzan P, Aguglia E, McGuire P, Mondelli V: The dietary pattern of patients with schizophrenia: a systematic review. J Psychiatr Res 2013; 47: 197–207.
22.
Royal B: Schizophrenia: nutrition and alternative treatment approaches. Schizophr Bull 2015; 42: 1083–1085.
23.
Andrade C: Cardiometabolic risks in schizophrenia and directions for intervention. 2. Nonpharmacological Interventions. J Clin Psychiatry 2016; 77:e964–e967.
24.
Peet M: International variations in the outcome of schizophrenia and the prevalence of depression in relation to national dietary practices: an ecological analysis. Br J Psychiatry 2004; 184: 404–408.
25.
Pearsall R, Thyarappa Praveen K, Pelosi A, Geddes J: Dietary advice for people with schizophrenia. Cochrane Database Syst Rev 2016; 3:CD009547.
26.
Sánchez-Villegas A, Martínez-González MA, Estruch R, Salas-Salvadó J, Corella D, Covas MI, Arós F, Romaguera D, Gómez-Gracia E, Lapetra J: Mediterranean dietary pattern and depression: the PREDIMED randomized trial. BMC Med 2013; 11: 208.
27.
Munoz M-A, Fíto M, Marrugat J, Covas M-I, Schröder H: Adherence to the Mediterranean diet is associated with better mental and physical health. Br J Nutr 2008; 101: 1821–1827.
28.
Trichopoulou A, Kouris-Blazos A, Wahlqvist ML, Gnardellis C, Lagiou P, Polychronopoulos E, Vassilakou T, Lipworth L, Trichopoulos D: Diet and overall survival in elderly people. BMJ 1995; 311: 1457–1460.
29.
Schwingshackl L, Hoffmann G: Does a Mediterranean-type diet reduce cancer risk? Curr Nutr Rep 2016; 5: 9–17.
30.
Stahl ST, Albert SM, Dew MA, Lockovich MH, Reynolds CF III: Coaching in healthy dietary practices in at-risk older adults: a case of indicated depression prevention. Am J Psychiatry 2014; 171: 499–505.
31.
Jacka FN, O’Neil A, Opie R, Itsiopoulos C, Cotton S, Mohebbi M, Castle D, Dash S, Mihalopoulos C, Chatterton ML: A randomised controlled trial of dietary improvement for adults with major depression (the “SMILES” trial). BMC Med 2017; 15: 23.
32.
Bersani FS, Biondi M, Coviello M, Fagiolini A, Majorana M, Minichino A, Rusconi AC, Vergnani L, Vicinanza R, Coccanari de’Fornari MA: Psychoeducational intervention focused on healthy living improves psychopathological severity and lifestyle quality in psychiatric patients: preliminary findings from a controlled study. J Mental Health 2017; 26: 271–275.
33.
Seo JH, Lee YM, Lee JS, Kang HC, Kim HD: Efficacy and tolerability of the ketogenic diet according to lipid:nonlipid ratios – comparison of 3: 1 with 4: 1 diet. Epilepsia 2007; 48: 801–805.
34.
Newell C, Bomhof MR, Reimer RA, Hittel DS, Rho JM, Shearer J: Ketogenic diet modifies the gut microbiota in a murine model of autism spectrum disorder. Mol Autism 2016; 7: 37.
35.
Ma D, Wang AC, Parikh I, Green SJ, Hoffman JD, Chlipala G, Murphy MP, Sokola BS, Bauer B, Hartz AM: Ketogenic diet enhances neurovascular function with altered gut microbiome in young healthy mice. Sci Rep 2018; 8: 6670.
36.
Bostock E, Kirkby KC, Taylor BV: The current status of the ketogenic diet in psychiatry. Front Psychiatry 2017; 8: 43.
37.
Graham TG, Ramsey D: The Happiness Diet: A Nutritional Prescription for a Sharp Brain, Balanced Mood, and Lean, Energized Body. Emmaus, Potter/Ten Speed/Harmony/Rodale, 2012.
38.
Mischoulon D, Freeman MP: Omega-3 fatty acids in psychiatry. Psychiatr Clin 2013; 36: 15–23.
39.
Harris WS, Von Schacky C: The Omega-3 Index: a new risk factor for death from coronary heart disease? Prev Med 2004; 39: 212–220.
40.
Sarris J, Mischoulon D, Schweitzer I: Omega-3 for bipolar disorder: meta-analyses of use in mania and bipolar depression. J Clin Psychiatry 2012; 73: 81–86.
41.
Lin P-Y, Huang S-Y, Su K-P: A meta-analytic review of polyunsaturated fatty acid compositions in patients with depression. Biol Psychiatry 2010; 68: 140–147.
42.
Rapaport MH, Nierenberg AA, Schettler PJ, Kinkead B, Cardoos A, Walker R, Mischoulon D: Inflammation as a predictive biomarker for response to omega-3 fatty acids in major depressive disorder: a proof-of-concept study. Mol Psychiatry 2016; 21: 71.
43.
Adams PB, Lawson S, Sanigorski A, Sinclair AJ: Arachidonic acid to eicosapentaenoic acid ratio in blood correlates positively with clinical symptoms of depression. Lipids 1996; 31(suppl):S157–S161.
44.
Bae J-H, Kim G: Systematic review and meta-analysis of omega-3-fatty acids in elderly patients with depression. Nutr Res 2018; 50: 1–9.
45.
Chia SC, Henry J, Mok YM, Honer WG, Sim K: Fatty acid and vitamin interventions in adults with schizophrenia: a systematic review of the current evidence. J Neural Transm 2015; 122: 1721–1732.
46.
Sharma A, Gerbarg P, Bottiglieri T, Massoumi L, Carpenter LL, Lavretsky H, Muskin PR, Brown RP, Mischoulon D: S-adenosylmethionine (SAMe) for neuropsychiatric disorders: a clinician-oriented review of research. J Clin Psychiatry 2017; 78:e656.
47.
Papakostas GI, Cassiello CF, Iovieno N: Folates and S-adenosylmethionine for major depressive disorder. Can J Psychiatry 2012; 57: 406–413.
48.
Sarris J, Price LH, Carpenter LL, Tyrka AR, Ng CH, Papakostas GI, Jaeger A, Fava M, Mi-schoulon D: Is S-adenosyl methionine (SAMe) for depression only effective in males? A re-analysis of data from a randomized clinical trial. Pharmacopsychiatry 2015; 48: 141.
49.
Galizia I, Oldani L, Macritchie K, Amari E, Dougall D, Jones TN, Lam RW, Massei GJ, Yatham L, Young AH: S-adenosyl methionine (SAM-e) for depression in adults. Cochrane Database Syst Rev 2016; 10:CD011286.
50.
Berk M, Malhi GS, Gray LJ, Dean OM: The promise of N-acetylcysteine in neuropsychiatry. Trends Pharmacol Sci 2013; 34: 167–177.
51.
Lai J, Moxey A, Nowak G, Vashum K, Bailey K, McEvoy M: The efficacy of zinc supplementation in depression: systematic review of randomised controlled trials. J Affect Disord 2012; 136:e31–e39.
52.
Martínez-Cengotitabengoa M, Carrascón L, O’Brien JT, Díaz-Gutiérrez M-J, Bermúdez-Ampudia C, Sanada K, Arrasate M, González-Pinto A: Peripheral inflammatory parameters in late-life depression: a systematic review. Int J Mol Sci 2016; 17: 2022.
53.
Pittenger C, Sanacora G, Krystal JH: The NMDA receptor as a therapeutic target in major depressive disorder. CNS Neurol Disord Drug Targets 2007; 6: 101–115.
54.
Fava M, Mischoulon D: Folate in depression: efficacy, safety, differences in formulations, and clinical issues. J Clin Psychiatry 2009; 70: 12–17.
55.
Papakostas GI, Shelton RC, Zajecka JM, Etemad B, Rickels K, Clain A, Baer L, Dalton ED, Sacco GR, Schoenfeld D: L-Methylfolate as adjunctive therapy for SSRI-resistant major depression: results of two randomized, double-blind, parallel-sequential trials. Am J Psychiatry 2012; 169: 1267–1274.
56.
Zhao G, Ford ES, Li C, Greenlund KJ, Croft JB, Balluz LS: Use of folic acid and vitamin supplementation among adults with depression and anxiety: a cross-sectional, population-based survey. Nutr J 2011; 10: 102.
57.
Bener A, Kamal M: Predict attention deficit hyperactivity disorder? Evidence-based medicine. Global J Health Sci 2014; 6: 47.
58.
Milaneschi Y, Hoogendijk W, Lips P, Heij-boer A, Schoevers R, Van Hemert A, Beekman A, Smit J, Penninx B: The association between low vitamin D and depressive disorders. Mol Psychiatry 2014; 19: 444.
59.
Belzeaux R, Boyer L, Féron F, Leboyer M, Fond G: Mood disorders are associated with a more severe hypovitaminosis D than schizophrenia. Psychiatry Res 2015; 229: 613–616.
60.
Spedding S: Vitamin D and depression: a systematic review and meta-analysis comparing studies with and without biological flaws. Nutrients 2014; 6: 1501–1518.
61.
Krivoy A, Onn R, Vilner Y, Hochman E, Weizman S, Paz A, Hess S, Sagy R, Kimhi-Nesher S, Kalter E: Vitamin D supplementation in chronic schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled clinical trial. EBioMedicine 2017; 26: 138–145.
62.
Lerner PP, Sharony L, Miodownik C: Association between mental disorders, cognitive disturbances and vitamin D serum level: current state. Clin Nutr ESPEN 2018; 23: 89–102.
63.
Rucklidge JJ, Johnstone J, Kaplan BJ: Magic bullet thinking – why do we continue to perpetuate this fallacy? Br J Psychiatry 2013; 203: 154–154.
64.
Turnbaugh PJ, Gordon JI: The core gut microbiome, energy balance and obesity. J Physiol 2009; 587: 4153–4158.
65.
Streit WR, Schmitz RA: Metagenomics – the key to the uncultured microbes. Curr Opin Microbiol 2004; 7: 492–498.
66.
Jandhyala SM, Talukdar R, Subramanyam C, Vuyyuru H, Sasikala M, Reddy DN: Role of the normal gut microbiota. World J Gastroenterol 2015; 21: 8787.
67.
Turnbaugh PJ, Ley RE, Hamady M, Fraser-Liggett CM, Knight R, Gordon JI: The human microbiome project. Nature 2007; 449: 804–810.
68.
Costello EK, Lauber CL, Hamady M, Fierer N, Gordon JI, Knight R: Bacterial community variation in human body habitats across space and time. Science 2009; 326: 1694–1697.
69.
Lozupone CA, Stombaugh JI, Gordon JI, Jansson JK, Knight R: Diversity, stability and resilience of the human gut microbiota. Nature 2012; 489: 220–230.
70.
Cryan JF, O’Mahony S: The microbiome-gut-brain axis: from bowel to behavior. Neurogastroenterol Motil 2011; 23: 187–192.
71.
Lv F, Chen S, Wang L, Jiang R, Tian H, Li J, Yao Y, Zhuo C: The role of microbiota in the pathogenesis of schizophrenia and major depressive disorder and the possibility of targeting microbiota as a treatment option. Oncotarget 2017; 8: 100899.
72.
Mörkl S, Lackner S, Müller W, Gorkiewicz G, Kashofer K, Oberascher A, Painold A, Holl A, Holzer P, Meinitzer A: Gut microbiota and body composition in anorexia nervosa inpatients in comparison to athletes, overweight, obese, and normal weight controls. Int J Eating Disord 2017; 50: 1421–1431.
73.
Foster JA, Neufeld K-AM: Gut-brain axis: how the microbiome influences anxiety and depression. Trends Neurosci 2013; 36: 305–312.
74.
Evrensel A, Ceylan ME: The gut-brain axis: the missing link in depression. Clin Psychopharmacol Neurosci 2015; 13: 239.
75.
Bravo JA, Forsythe P, Chew MV, Escaravage E, Savignac HM, Dinan TG, Bienenstock J, Cryan JF: Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve. Proc Natl Acad Sci 2011; 108: 16050–16055.
76.
Arseneault-Bréard J, Rondeau I, Gilbert K, Girard S-A, Tompkins TA, Godbout R, Rousseau G: Combination of Lactobacillus helveticus R0052 and Bifidobacterium longum R0175 reduces post-myocardial infarction depression symptoms and restores intestinal permeability in a rat model. Br J Nutr 2012; 107: 1793–1799.
77.
Mörkl S, Lackner S, Meinitzer A, Mangge H, Lehofer M, Halwachs B, Gorkiewicz G, Kashofer K, Painold A, Holl A: Gut microbiota, dietary intakes and intestinal permeability reflected by serum zonulin in women. Eur J Nutr 2018, Epub ahead of print.
78.
Haroon E, Raison CL, Miller AH: Psychoneuroimmunology meets neuropsychopharmacology: translational implications of the impact of inflammation on behavior. Neuropsychopharmacology 2012; 37: 137.
79.
Sherwin E, Rea K, Dinan TG, Cryan JF: A gut (microbiome) feeling about the brain. Curr Opin Gastroenterol 2016; 32: 96–102.
80.
Lichtblau N, Schmidt FM, Schumann R, Kirkby KC, Himmerich H: Cytokines as biomarkers in depressive disorder: current standing and prospects. Int Rev Psychiatry 2013; 25: 592–603.
81.
Quagliato LA, Nardi AE: Cytokine alterations in panic disorder: a systematic review. J Affect Disord 2018; 228: 91–96.
82.
Felger JC, Lotrich FE: Inflammatory cytokines in depression: neurobiological mechanisms and therapeutic implications. Neuroscience 2013; 246: 199–229.
83.
Krügel U, Fischer J, Radicke S, Sack U, Himmerich H: Antidepressant effects of TNF-α blockade in an animal model of depression. J Psychiatr Res 2013; 47: 611–616.
84.
Himmerich H, Treasure J: Psychopharmacological advances in eating disorders. Expert Rev Clin Pharmacol 2018; 11: 95–108.
85.
Catena-Dell’Osso M, Rotella F, Dell’Osso A, Fagiolini A, Marazziti D: Inflammation, serotonin and major depression. Curr Drug Targets 2013; 14: 571–577.
86.
Appelhans BM, Whited MC, Schneider KL, Ma Y, Oleski JL, Merriam PA, Waring ME, Olendzki BC, Mann DM, Ockene IS: Depression severity, diet quality, and physical activity in women with obesity and depression. J Acad Nutr Dietet 2012; 112: 693–698.
87.
Shoelson SE, Herrero L, Naaz A: Obesity, inflammation, and insulin resistance. Gastroenterology 2007; 132: 2169–2180.
88.
Ramnani P, Costabile A, Bustillo A, Gibson GR: A randomised, double-blind, cross-over study investigating the prebiotic effect of agave fructans in healthy human subjects. J Nutr Sci 2015; 4:e10.
89.
Tarr AJ, Galley JD, Fisher SE, Chichlowski M, Berg BM, Bailey MT: The prebiotics 3′ sialyllactose and 6′ sialyllactose diminish stressor-induced anxiety-like behavior and colonic microbiota alterations: evidence for effects on the gut-brain axis. Brain Behav Immunity 2015; 50: 166–177.
90.
Metchnikoff E, Mitchell PC: The Prolongation of Life: Optimistic Studies. London, Putnam, 1908.
91.
Savignac H, Kiely B, Dinan T, Cryan J: Bifidobacteria exert strain-specific effects on stress-related behavior and physiology in BALB/c mice. Neurogastroenterol Motil 2014; 26: 1615–1627.
92.
Tillisch K, Labus J, Kilpatrick L, Jiang Z, Stains J, Ebrat B, Guyonnet D, Legrain-Raspaud S, Trotin B, Naliboff B: Consumption of fermented milk product with probiotic modulates brain activity. Gastroenterology 2013; 144: 1394–1401. e1394.
93.
Messaoudi M, Violle N, Bisson J-F, Desor D, Javelot H, Rougeot C: Beneficial psychological effects of a probiotic formulation (Lactobacillus helveticus R0052 and Bifidobacterium longum R0175) in healthy human volunteers. Gut Microbes 2011; 2: 256–261.
94.
Akkasheh G, Kashani-Poor Z, Tajabadi-Ebrahimi M, Jafari P, Akbari H, Taghizadeh M, Memarzadeh MR, Asemi Z, Esmaillzadeh A: Clinical and metabolic response to probiotic administration in patients with major depressive disorder: a randomized, double-blind, placebo-controlled trial. Nutrition 2016; 32: 315–320.
95.
Bambling M, Edwards SC, Hall S, Vitetta L: A combination of probiotics and magnesium orotate attenuate depression in a small SSRI resistant cohort: an intestinal anti-inflammatory response is suggested. Inflammopharmacology 2017; 25: 271–274.
96.
Romijn AR, Rucklidge JJ, Kuijer RG, Frampton C: A double-blind, randomized, placebo-controlled trial of Lactobacillus helveticus and Bifidobacterium longum for the symptoms of depression. Aust NZ J Psychiatry 2017; 51: 810–821.
97.
Slyepchenko A, Maes M, Jacka FN, Köhler CA, Barichello T, McIntyre RS, Berk M, Grande I, Foster JA, Vieta E: Gut microbiota, bacterial translocation, and interactions with diet: pathophysiological links between major depressive disorder and non-communicable medical comorbidities. Psychother Psychosom 2017; 86: 31–46.
98.
Fond G, Boukouaci W, Chevalier G, Re-gnault A, Eberl G, Hamdani N, Dickerson F, Macgregor A, Boyer L, Dargel A: The “psychomicrobiotic”: targeting microbiota in major psychiatric disorders: a systematic review. Pathol Biol 2015; 63: 35–42.
99.
Dickerson FB, Stallings C, Origoni A, Katsafanas E, Savage CL, Schweinfurth LA, Goga J, Khushalani S, Yolken RH: Effect of probiotic supplementation on schizophrenia symptoms and association with gastrointestinal functioning: a randomized, placebo-controlled trial. Prim Care Companion CNS Disord 2014; 16: 13m01579.
100.
Lieb J: The immunostimulating and antimicrobial properties of lithium and antidepressants. J Infect 2004; 49: 88–93.
101.
Munoz-Bellido J, Munoz-Criado S, Garcìa-Rodrìguez J: Antimicrobial activity of psychotropic drugs: selective serotonin reuptake inhibitors. Int J Antimicrob Agents 2000; 14: 177–180.
102.
Le Bastard Q, Al-Ghalith G, Grégoire M, Chapelet G, Javaudin F, Dailly E, Batard E, Knights D, Montassier E: Systematic review: human gut dysbiosis induced by non-antibiotic prescription medications. Aliment Pharmacol Therapeutics 2018; 47: 332–345.
103.
Tsilingiri K, Rescigno M: Postbiotics: what else? Benef Microbes 2012; 4: 101–107.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.